Erratum (DOI:10.1016/j.biopsych.2007.04.040);The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the Acute and Continuation Phases

Biological Psychiatry

Volumn 62, Issue 12, 2007, Pages 1371-1379

  Keller, Martin B ^a   Trivedi, Madhukar H ^b   Thase, Michael E ^c   Shelton, Richard C ^d   Kornstein, Susan G ^e   Nemeroff, Charles B ^f   Friedman, Edward S ^c   Gelenberg, Alan J ^g   Kocsis, James H ^h   Dunner, David L ⁱ   Dunlop, Boadie W ^f   Hirschfeld, Robert M ^j   Rothschild, Anthony J ^k   Ferguson, James M ^l   Schatzberg, Alan F ^m   Zajecka, John M ⁿ   Pedersen, Ron ^o   Yan, Bing ^o   Ahmed, Saeeduddin ^o   Schmidt, Michael ^o   Ninan, Philip T ^o   more..

^a BROWN UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d VANDERBILT UNIVERSITY   (United States)

^e VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^f EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF ARIZONA   (United States)

^h WEILL CORNELL MEDICAL COLLEGE   (United States)

ⁱ Center for Anxiety and Depression   (United States)

^j UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^k UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^l UNIVERSITY OF UTAH   (United States)

^m STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁿ RUSH UNIVERSITY MEDICAL CENTER   (United States)

^o PFIZER INC   (United States)

more..

Author keywords

Acute therapy; antidepressants; continuation therapy; fluoxetine; major depression; venlafaxine ER

Indexed keywords

FLUOXETINE; VENLAFAXINE;

ACCIDENTAL INJURY; ADULT; ANOREXIA; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG RELEASE; FEMALE; GASTROENTERITIS; HAMILTON SCALE; HEADACHE; HUMAN; IMPOTENCE; INFECTION; INSOMNIA; LIBIDO; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MULTICENTER STUDY; NAUSEA; NERVOUSNESS; OUTPATIENT CARE; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REMISSION; SIDE EFFECT; SOMNOLENCE; SWEATING; TINNITUS; TREATMENT DURATION; TREATMENT OUTCOME; TREMOR; UPPER RESPIRATORY TRACT INFECTION; WEIGHT REDUCTION; XEROSTOMIA; YAWNING;

EID: 36549069307     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2008.02.009     Document Type: Erratum

References (38)

1. Keller M.B., Lavori P.W., Lewis C.E., and Klerman G.L. Predictors of relapse in major depressive disorder. JAMA 250 (1983) 3299-3304
2. Solomon D.A., Keller M.B., Leon A.C., Mueller T.I., Lavori P.W., Shea M.T., et al. Multiple recurrences of major depressive disorder. Am J Psychiatry 157 (2000) 229-233
3. Aberg-Wistedt A., Agren H., Ekselius L., Bengtsson F., and Akerblad A.C. Sertraline versus paroxetine in major depression: Clinical outcome after six months of continuous therapy. J Clin Psychopharmacol 20 (2000) 645-652
4. Montgomery S.A., Rasmussen J.G., and Tanghoj P. A 24-week study of 20 mg citalopram, 40 mg citalopram, and placebo in the prevention of relapse of major depression. Int Clin Psychopharmacol 8 (1993) 181-188
5. Montgomery S.A., Reimitz P.E., and Zivkov M. Mirtazapine versus amitriptyline in the long-term treatment of depression: A double-blind placebo-controlled study. Int Clin Psychopharmacol 13 (1998) 63-73
6. Simon J.S., Aguiar L.M., Kunz N.R., and Lei D. Extended-release venlafaxine in relapse prevention for patients with major depressive disorder. J Psychiatr Res 38 (2004) 249-257
7. Lepine J.P., Caillard V., Bisserbe J.C., Troy S., Hotton J.M., and Boyer P. A randomized, placebo-controlled trial of sertraline for prophylactic treatment of highly recurrent major depressive disorder. Am J Psychiatry 161 (2004) 836-842
8. Gilaberte I., Montejo A.L., de la Gandara J., Perez-Sola V., Bernardo M., Massana J., et al. Fluoxetine in the prevention of depressive recurrences: A double-blind study. J Clin Psychopharmacol 21 (2001) 417-424
9. Hochstrasser B., Isaksen P.M., Koponen H., Lauritzen L., Mahnert F.A., Rouillon F., et al. Prophylactic effect of citalopram in unipolar, recurrent depression: Placebo-controlled study of maintenance therapy. Br J Psychiatry 178 (2001) 304-310
10. Montgomery S.A., Entsuah R., Hackett D., Kunz N.R., and Rudolph R.L. Venlafaxine versus placebo in the preventive treatment of recurrent major depression. J Clin Psychiatry 65 (2004) 328-336
11. Frank E., Kupfer D.J., Perel J.M., Cornes C., Jarrett D.B., Mallinger A.G., et al. Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 47 (1990) 1093-1099
12. Judd L.L., Akiskal H.S., Maser J.D., Zeller P.J., Endicott J., Coryell W., et al. Major depressive disorder: A prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord 50 (1998) 97-108
13. Judd L.L., Paulus M.J., Schettler P.J., Akiskal H.S., Endicott J., Leon A.C., et al. Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness?. Am J Psychiatry 157 (2000) 1501-1504
14. Thase M.E., Entsuah A.R., and Rudolph R.L. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 178 (2001) 234-241
15. Smith D., Dempster C., Glanville J., Freemantle N., and Anderson I. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: A meta-analysis. Br J Psychiatry 180 (2002) 396-404
16. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) (1994), American Psychiatric Association, Washington, DC
17. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 23 (1960) 56-62
18. Rush A.J., Giles D.E., Schlesser M.A., Fulton C.L., Weissenburger J., and Burns C. The Inventory for Depressive Symptomatology (IDS): Preliminary findings. Psychiatry Res 18 (1986) 65-87
19. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 32 (1959) 50-55
20. Guy W. Clinical global impressions. ECDEU Assessment Manual for Psychopharmacology, Revised (1976), US Department of Health, Education and Welfare, National Institute of Mental Health, Bethesda, MD 217-222
21. Weissman M.M., and Bothwell S. Assessment of social adjustment by patient self-report. Arch Gen Psychiatry 33 (1976) 1111-1115
22. Keller M.B., Lavori P.W., Friedman B., Nielsen E., Endicott J., McDonald-Scott P., et al. The Longitudinal Interval Follow-up Evaluation. A comprehensive method for assessing outcome in prospective longitudinal studies. Arch Gen Psychiatry 44 (1987) 540-548
23. Fawcett J., Clark D.C., Scheftner W.A., and Gibbons R.D. Assessing anhedonia in psychiatric patients. Arch Gen Psychiatry 40 (1983) 79-84
24. Ware J.E., and Snow K.K. SF-36 Health Survey Manual and Information Guide (1993), The Health Institute, New England Medical Center, Boston
25. Endicott J., Nee J., Harrison W., and Blumenthal R. Quality of Life Enjoyment and Satisfaction Questionnaire: A new measure. Psychopharmacol Bull 29 (1993) 321-326
26. Keller M.B., Kocsis J.H., Thase M.E., Gelenberg A.J., Rush A.J., Koran L., et al. Maintenance phase efficacy of sertraline for chronic depression: A randomized controlled trial. JAMA 280 (1998) 1665-1672
27. Bielski R.J., Ventura D., and Chang C.C. A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatry 65 (2004) 1190-1196
28. Detke M.J., Lu Y., Goldstein D.J., Hayes J.R., and Demitrack M.A. Duloxetine, 60 mg once daily, for major depressive disorder: A randomized double-blind placebo-controlled trial. J Clin Psychiatry 63 (2002) 308-315
29. Rudolph R.L., and Feiger A.D. A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. J Affect Disord 56 (1999) 171-181
30. Silverstone P.H., and Ravindran A. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group. J Clin Psychiatry 60 (1999) 22-28
31. Suri R.A., Altshuler L.L., Rasgon N.L., Calcagno J.L., Frye M.A., Gitlin M.J., et al. Efficacy and response time to sertraline versus fluoxetine in the treatment of unipolar major depressive disorder. J Clin Psychiatry 61 (2000) 942-946
32. Trivedi M.H., Pigotti T.A., Perera P., Dillingham K.E., Carfagno M.L., and Pitts C.D. Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder. J Clin Psychiatry 65 (2004) 1356-1364
33. Trivedi M.H., Rush A.J., Wisniewski S.R., Nierenberg A.A., Warden D., Ritz L., et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice. Am J Psychiatry 163 (2006) 28-40
34. Cipriani A., Brambilla P., Furukawa T., Geddes J., Gregis M., Hotopf M., et al. Fluoxetine versus other types of pharmacotherapy for depression. Cochrane Database Syst Rev 4 (2005) CD004185
35. Nemeroff CB, Entsuah R, Benattia I, Demitrack M, Thase ME (submitted): Comprehensive analysis of remission (ComPARE) with venlafaxine vs SSRIs. Biol Psychiatry.
36. Edwards J.G., and Anderson I. Systematic review and guide to selection of selective serotonin reuptake inhibitors. Drugs 57 (1999) 507-533
37. Heres S., Davis J., Maino K., Jetzinger E., Kissling W., and Leucht S. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: An exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry 163 (2006) 185-194
38. Thase M.E. Comparing the methods used to compare antidepressants. Psychopharmacol Bull 36 suppl 1 (2002) 4-17